Jane Healy Takes on Leadership Role at Photocure as EMEA General Manager

Photocure Announces New Vice President and General Manager for EMEA

On March 26, 2025, Photocure ASA, recognized as the Bladder Cancer Company, made an important announcement regarding its leadership. Jane Healy has been appointed as the new Vice President and General Manager for the EMEA (Europe, Middle East, and Africa) region. This strategic move highlights Photocure’s commitment to expanding its footprint in the uro-oncology market and enhancing its capabilities in delivering innovative solutions to bladder cancer patients.

Jane Healy’s journey with Photocure began earlier this month. With over three decades of experience in the medical device industry, she has cultivated a rich background in various domains including sales, marketing, general management, and functional leadership. Her career has seen her take significant roles at major organizations, including St. Jude Medical, CR Bard, and Boston Scientific, where she dedicated more than 20 years. In her last capacity at Boston Scientific, she served as the VP for EMEA in the Peripheral Interventions Division, where she spearheaded regional growth strategies.

Healy's expertise is multifaceted; she possesses a robust commercial mindset coupled with a results-driven approach. Her leadership style emphasizes enabling teams to achieve their full potential, which is essential as Photocure navigates the evolving healthcare landscape in uro-oncology.

Dan Schneider, President and CEO of Photocure, expressed enthusiasm over Healy’s appointment. "I am pleased to welcome Jane to the Photocure team at such an important time for us. Her background and extensive experience in healthcare and medical devices will be instrumental in achieving our growth ambitions in uro-oncology. Her track record of building successful international teams make her the ideal fit to lead Photocure's European Organization, at a time when the Uro-Oncology world is experiencing tremendous innovation and attention in healthcare."

As part of her role, Healy will report directly to Schneider and will be a key member of Photocure's executive leadership team. Her responsibilities will involve steering the European Organization, which has been pivotal since the company regained sales, marketing, and distribution rights for Hexvix® in Europe from Ipsen Pharma SAS on October 1, 2020. The reintroduction of BLC (Blue Light Cystoscopy) to the European market has already seen positive momentum, and Healy's leadership is expected to further this progress.

"I look forward to Jane's leadership as we continue pursuing our ambition to lead the change that will improve the lives of bladder cancer patients. We know the importance of using Blue Light Cystoscopy in the precision diagnostic pathway for bladder cancer, where accurate staging and resection helps determine optimal treatment decisions," Schneider stated.

Bladder cancer poses significant challenges in healthcare, with it being the eighth most common cancer globally and significantly affecting men. It has a high recurrence rate, and patients often require multiple cystoscopies. Innovative diagnostic solutions like Blue Light Cystoscopy, especially in conjunction with the drug Hexvix/Cysview, are crucial in enhancing detection and management of the disease. These innovative technologies allow cancer cells to glow during cystoscopy, aiding in tumor identification and resection.

With Jane Healy at the helm for the EMEA region, Photocure seeks to drive advancements in uro-oncology while addressing the pressing needs of bladder cancer patients. As the company continues to push for transformative outcomes through its unique solutions, Healy’s leadership is expected to play a key role in shaping the future of bladder cancer care globally.

For more information about Photocure and its innovative products, you can visit Photocure's official website.